Abstract
The on-going coronavirus disease 2019 (COVID-19) pandemic has mobilized a global effort to develop vaccines and therapeutics that inhibit viral entry by inducing or transferring antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (CoV2-S). Phase I/II vaccine clinical trials, monoclonal antibodies, and convalescent sera have all shown promise. However, these efforts often require extensive screening with the live virus under onerous high biocontainment conditions (BSL-3). Virus neutralization assays (VNAs) remain the gold standard for evaluating the anti-viral potency of antibodies and entry inhibitors. The proliferation of pseudotyped virus systems that can be used in BSL-2 compatible VNAs is a positive development. Yet, there is marked variability between VNAs and how the findings are presented, making inter-group comparisons difficult. To address these limitations, we developed a standardized VNA using VSVΔG based CoV-2-S pseudotyped particles (CoV2pp) that can be robustly produced at scale. We used our CoV2pp to interrogate the role of exogenous and endogenous proteases in CoV-2-S mediated entry and standardized our VNA based on that understanding. Our CoV2pp VNA showed a strong positive correlation with CoV2-S ELISA and live virus neutralizations in a validated set of patient sera. Our system was subsequently validated by three independent groups as an “out-of-the-box” VNA. More than 120 patient sera were screened, and we report descriptive statistics for absolute (abs) IC50, IC80, and IC90 values from all positive patient sera. Lastly, we used our CoV2pp in a screen to identify ultrapermissive 293T clones that stably express ACE2 or ACE2+TMPRSS2. When used in combination with our CoV2pp, we can now produce CoV2pp sufficient for 150,000 standardized VNA/week.
Competing Interest Statement
The Icahn School of Medicine at Mount Sinai has filed for a U.S. Provisional Patent (Application Number 63/063,041) for the work presented here.
Funding Statement
The authors acknowledge the following funding: KYO and CS were supported by Viral-Host Pathogenesis Training Grant T32 AI07647; KYO was additionally supported by F31 AI154739. SI and CTH were supported by postdoctoral fellowships from CHOT-SG (Fukuoka University, Japan) and the Ministry of Science and Technology (MOST, Taiwan), respectively. BL acknowledges flexible funding support from NIH grants R01 AI123449, R21 AI1498033, and the Department of Microbiology and the Ward-Coleman estate for endowing the Ward-Coleman Chairs at the ISMMS. JPK and SSI acknowledge funding from a LSUHS COVID-19 intramural grant. JPK and SSI acknowledge additional funding from NIH grants AI116851 and AI143839, respectively. This work was further supported by the Microbiology Laboratory Clinical Services at the Mount Sinai Health System and the Mount Sinai Health System Translational Science Hub, NIH grant U54TR001433 to the Department of Medicine of the ISMMS to SZP. We also acknowledge funding from the Department of Veterans Affairs Merit Review Grant I01BX003860 (CEH, SZP, and JK), Research Career Scientist Award 1IK6BX004607 (CEH), and NIH grant AI139290 (CEH, SZP). We thank Randy A. Albrecht for oversight of the conventional BSL3 biocontainment facility. Work in the Krammer laboratory was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C (FK), Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051 (FK) and the generous support of the JPB foundation, the Open Philanthropy Project (#2020-215611) and other philanthropic donations.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All patient sera were acquired after approval by the respective institutional review boards and/or equivalent oversight bodies (Bioethics Committee, Independent Ethics Committee) are indicated: (1) Mount Sinai Hospital Institutional Review Board (New York, USA), (2) Louisiana State University Health Sciences Center, Shreveport (LSUHS, Louisiana, USA), and (3) Fundacion Instituto Leloir-CONICET, Universidad Nacional de San Martin, Laboratorio Lemos SRL, Universidad de Buenos Aires (COVIDAR Argentina Consortium, Buenos Aires, Argentina). Samples were de-identified at the source institutions or by the respective PIs of the IRB approved protocols for sample collection before analysis performed in this study. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
i. Fundacion Instituto Leloir-CONICET, Buenos Aires, Argentina
ii. Universidad Nacional de San Martin, Buenos Aires, Argentina
iii. Laboratorio Lemos SRL, Buenos Aires, Argentina
iv. INBIRS-CONICET, Facultad de Medicina, Universidad de Buenos Aires, Argentina
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article and/or its supplementary materials.
